Conformational properties of the disaccharide building units of hyaluronan.

P. Pogány,A. Kovács

DOI: https://doi.org/10.1016/j.carres.2009.05.030

IF: 2.975

2009-09-08

Carbohydrate Research

Abstract:

What problem does this paper attempt to address?

Acute Respiratory Distress Syndrome: Bench-to-Bedside Approaches to Improve Drug Development.

Musaddique Hussain,Chengyun Xu,Mashaal Ahmad,Abdul Majeed,Meiping Lu,Xiling Wu,Lanfang Tang,Ximei Wu

DOI: https://doi.org/10.1002/cpt.1034

2018-01-01

Clinical Pharmacology & Therapeutics

Abstract:Despite 50 years of extensive research, no definite drug is currently available to treat acute respiratory distress syndrome (ARDS), and the supportive therapies remain the mainstay of treatment. To improve drug development for ARDS, researchers need to deeply analyze the omics approaches, reevaluate the suitable therapeutic targets, resolve the problems of inadequate animal modeling, develop the strategies to reduce the heterogeneity, and reconsider new therapeutic and analytical approaches for better designs of clinical trials.
Acute Respiratory Distress Syndrome: Bench‐to‐Bedside Approaches to Improve Drug Development

Musaddique Hussain,Chengyun Xu,Mashaal Ahmad,Abdul Majeed,Meiping Lu,Xiling Wu,Lanfang Tang,Ximei Wu

DOI: https://doi.org/10.1002/cpt.1034

2018-01-01

Abstract:Despite 50 years of extensive research, no definite drug is currently available to treat acute respiratory distress syndrome (ARDS), and the supportive therapies remain the mainstay of treatment. To improve drug development for ARDS, researchers need to deeply analyze the “omics” approaches, reevaluate the suitable therapeutic targets, resolve the problems of inadequate animal modeling, develop the strategies to reduce the heterogeneity, and reconsider new therapeutic and analytical approaches for better designs of clinical trials.
Challenges in ARDS Definition, Management, and Identification of Effective Personalized Therapies

F. Cruz,L. Ball,P. Rocco,C. Robba,P. Pelosi,D. Battaglini,Brigitta Fazzini,P. Silva

DOI: https://doi.org/10.3390/jcm12041381

IF: 3.9

2023-02-01

Journal of Clinical Medicine

Abstract:Over the last decade, the management of acute respiratory distress syndrome (ARDS) has made considerable progress both regarding supportive and pharmacologic therapies. Lung protective mechanical ventilation is the cornerstone of ARDS management. Current recommendations on mechanical ventilation in ARDS include the use of low tidal volume (VT) 4–6 mL/kg of predicted body weight, plateau pressure (PPLAT) < 30 cmH2O, and driving pressure (∆P) < 14 cmH2O. Moreover, positive end-expiratory pressure should be individualized. Recently, variables such as mechanical power and transpulmonary pressure seem promising for limiting ventilator-induced lung injury and optimizing ventilator settings. Rescue therapies such as recruitment maneuvers, vasodilators, prone positioning, extracorporeal membrane oxygenation, and extracorporeal carbon dioxide removal have been considered for patients with severe ARDS. Regarding pharmacotherapies, despite more than 50 years of research, no effective treatment has yet been found. However, the identification of ARDS sub-phenotypes has revealed that some pharmacologic therapies that have failed to provide benefits when considering all patients with ARDS can show beneficial effects when these patients were stratified into specific sub-populations; for example, those with hyperinflammation/hypoinflammation. The aim of this narrative review is to provide an overview on current advances in the management of ARDS from mechanical ventilation to pharmacological treatments, including personalized therapy.

Medicine
Pulmonary drug delivery for acute respiratory distress syndrome

Qinqin Fei,Ian Bentley,Samir N. Ghadiali,Joshua A. Englert

DOI: https://doi.org/10.1016/j.pupt.2023.102196

IF: 3.282

2023-04-01

Pulmonary Pharmacology & Therapeutics

Abstract:The acute respiratory distress syndrome (ARDS) is a life-threatening condition that causes respiratory failure. Despite numerous clinical trials, there are no molecularly targeted pharmacologic therapies to prevent or treat ARDS. Drug delivery during ARDS is challenging due to the heterogenous nature of lung injury and occlusion of lung units by edema fluid and inflammation. Pulmonary drug delivery during ARDS offers several potential advantages including limiting the off-target and off-organ effects and directly targeting the damaged and inflamed lung regions. In this review we summarize recent ARDS clinical trials using both systemic and pulmonary drug delivery. We then discuss the advantages of pulmonary drug delivery and potential challenges to its implementation. Finally, we discuss the use of nanoparticle drug delivery and surfactant-based drug carriers as potential strategies for delivering therapeutics to the injured lung in ARDS.

pharmacology & pharmacy,respiratory system
Management of the acute respiratory distress syndrome

Steven A Conrad,Akhil Bidani

DOI: https://doi.org/10.1016/s1052-3359(02)00012-1

Abstract:Significant advances have occurred in the knowledge of the pathogenesis of ARDS. It is now recognized that ARDS is a manifestation of a diffuse process that results from a complicated cascade of events following an initial insult or injury. Mechanical ventilation and PEEP are still important components of supportive therapy. To avoid ventilator-associated lung injury there is emphasis on targeting ventilator management based on measurement of pulmonary mechanics. For those with resistant hypoxia and severe pulmonary hypertension adjunctive modalities, such as prone positioning and low-dose iNO, may provide important benefit. Alternative modes of supporting gas exchange, such as with partial liquid ventilation and extracorporeal gas-exchange, may serve as rescue therapies. Advances in cell and molecular biology have contributed to a better understanding of the role of inflammatory cells and mediators that contribute to the acute lung injury and the pathophysiology of the syndrome that manifests as ARDS. Based on this new understanding, the potential targets for intervention to ameliorate the systemic inflammatory response have proliferated. Examples include the cytokine network and its receptors, antioxidants, and endothelins. Apart from the challenge of testing these agents in experimental models, it seems likely that determination of the optimum combination of agents will become an equally important endeavor. A particular challenge is to develop better methods of predicting which of the many at-risk patients will go on to full-blown ARDS and MODS, thereby targeting subgroups of patients most likely to benefit from anti-inflammatory therapies. Similarly, the adverse effects of immunosuppressive therapy may be diminished by improved, perhaps molecular, techniques to detect microbial pathogens and permit differentiation between Systemic inflammatory response syndrome and sepsis.
Share First, Save Later: Performance of Self through Snapchat Stories

Sarah McRoberts,Haiwei Ma,Andrew Hall,S. Yarosh

DOI: https://doi.org/10.1145/3025453.3025771

2017-05-02

Abstract:As the third most popular social network among millennials, Snapchat is well known for its picture and video messaging system that deletes content after it is viewed. However, the Stories feature of Snapchat offers a different perspective of ephemeral content sharing, with pictures and videos that are available for friends to watch an unlimited number of times for 24 hours. We conduct-ed an in-depth qualitative investigation by interviewing 18 participants and reviewing 14 days of their Stories posts. We identify five themes focused on how participants perceive and use the Stories feature, and apply a Goffmanesque metaphor to our analysis. We relate the Stories medium to other research on self-presentation and identity curation in social media.
Investigational pharmacological agents for the treatment of ARDS

Katyayini Aribindi,Michelle Lim,Satyan Lakshminrusimha,Timothy Albertson,Katyayini AribindiMichelle LimSatyan LakshminrusimhaTimothy Albertsona Department of Internal Medicine,Division of Pulmonary,Critical Care & Sleep Medicine,U.C. Davis School of Medicine,Sacramento,CA,USAb Department of Medicine,Veterans Affairs North California Health Care System,Mather,CA,USAc Department of Pediatrics,Division of Pediatric Critical Care Medicine,U.C. Davis School of Medicine,Sacramento,CA,USAd Department of Pediatrics,Division of Neonatal-Perinatal Medicine,U.C. Davis School of Medicine,Sacramento,CA,USA

DOI: https://doi.org/10.1080/13543784.2024.2315128

2024-02-28

Expert Opinion on Investigational Drugs

Abstract:Introduction Acute Respiratory Distress Syndrome (ARDS) is a heterogeneous form of lung injury with severe hypoxemia and bilateral infiltrates after an inciting event that results in diffuse lung inflammation with a high mortality rate. While research in COVID-related ARDS has resulted in several pharmacotherapeutic agents that have undergone successful investigation, non-COVID ARDS studies have not resulted in many widely accepted pharmacotherapeutic agents despite exhaustive research.

pharmacology & pharmacy
[Consensus conference: home intravenous antibiotic treatment for cystic fibrosis. The Sira Carrasco Foundation. 26 April 2002].

A. Salcedo,R. Girón,B. Beltrán,Ana Meca Martínez,Luis Máiz,L. Suárez,Fundación Sira Carrasco

2003-10-01

Archivos de Bronconeumologia

Abstract:Cystic fibrosis (CF) is the most common terminal genetic illness amongst Caucasians. The median survival age has increased more dramatically over the last 25 years than for any other chronic illness,1 reaching 33.4 years by 2001, according to the American Cystic Fibrosis Foundation.2 The improvement in survival of CF patients has meant that the number of CF patients over the age of 18 years has increased from 8% in 1970 to 39.5% in 2001, in the USA.2 Exacerbations and hospitalization increase after the first ten years of CF patients’ lives, so patients and their families are familiar with many treatment effects and there is no reason why treatment should not be carried out in the patient’s home. According to data from the American Cystic Fibrosis Foundation for 2001, cultures of respiratory secretions were positive for Pseudomonas aeruginosa in 58.8% of cases, Staphylococcus aureus in 48%, Burkholderia cepacia in 3.1%, and Stenotrophomonas maltophilia in 8.4%. The only data available for Spain were collected in 1997 by the Federación Española contra la Fibrosis Quística. Only 15 CF units out of the whole country participated in this registry, which included a total of 823 patients with a median age of 15.1 years. Microbiological findings for these patients revealed that 37.06% were colonized with P aeruginosa, 35.60% with S aureus, 12.88% with Haemophilus influenzae, 2.79% with S malthophilia, 1.94% with B. cepacia, and 15.9% were not colonized by any germ. Intravenous (IV) antibiotic treatment is normally given to patients with moderate to severe respiratory exacerbations, or in cycles for patients chronically colonized by P aeruginosa, mucoid phenotype. In the latter case, adverse effects such as allergic reactions to antibiotics or increased bacterial resistance to antibiotics are more common. Nearly 2.5 times more adults than children currently elect home intravenous antibiotic treatment (HIVAT). According to data from the American Cystic Fibrosis Foundation, HIVAT use increased from 12% in 1990 to 20.3% in 2001.2 In order to discover the current situation of HIVAT for CF patients in Spain, the Sira Carrasco Foundation in aid of CF organized a consensus conference for specialists involved in CF, in Madrid on April 26, 2002. Two months prior to the conference, a letter was sent to all the CF units in Spain, saying that on the web page of the Sira Carrasco Foundation (www.fundacionfibrosisquistica.org) there was a questionnaire on HIVAT to be filled in and sent by Internet or post. The data from the questionnaires was statistically processed and the results discussed and consensus reached at the conference. Twenty CF units participated; among them they control 1230 patients, 740 younger than 18 years of age and 490 older. This document summarizes the consensus reached on different questions related to HIVAT and the resulting recommendations.
Signaling pathways and potential therapeutic targets in acute respiratory distress syndrome (ARDS)

Qianrui Huang,Yue Le,Shusheng Li,Yi Bian

DOI: https://doi.org/10.1186/s12931-024-02678-5

IF: 5.8

2024-01-16

Respiratory Research

Abstract:Acute respiratory distress syndrome (ARDS) is a common condition associated with critically ill patients, characterized by bilateral chest radiographical opacities with refractory hypoxemia due to noncardiogenic pulmonary edema. Despite significant advances, the mortality of ARDS remains unacceptably high, and there are still no effective targeted pharmacotherapeutic agents. With the outbreak of coronavirus disease 19 worldwide, the mortality of ARDS has increased correspondingly. Comprehending the pathophysiology and the underlying molecular mechanisms of ARDS may thus be essential to developing effective therapeutic strategies and reducing mortality. To facilitate further understanding of its pathogenesis and exploring novel therapeutics, this review provides comprehensive information of ARDS from pathophysiology to molecular mechanisms and presents targeted therapeutics. We first describe the pathogenesis and pathophysiology of ARDS that involve dysregulated inflammation, alveolar-capillary barrier dysfunction, impaired alveolar fluid clearance and oxidative stress. Next, we summarize the molecular mechanisms and signaling pathways related to the above four aspects of ARDS pathophysiology, along with the latest research progress. Finally, we discuss the emerging therapeutic strategies that show exciting promise in ARDS, including several pharmacologic therapies, microRNA-based therapies and mesenchymal stromal cell therapies, highlighting the pathophysiological basis and the influences on signal transduction pathways for their use.

respiratory system
Antioxidants as Therapeutic Agents in Acute Respiratory Distress Syndrome (ARDS) Treatment—From Mice to Men

Andreas von Knethen,Ulrike Heinicke,Volker Laux,Michael J. Parnham,Andrea U. Steinbicker,Kai Zacharowski

DOI: https://doi.org/10.3390/biomedicines10010098

IF: 4.757

2022-01-04

Biomedicines

Abstract:Acute respiratory distress syndrome (ARDS) is a major cause of patient mortality in intensive care units (ICUs) worldwide. Considering that no causative treatment but only symptomatic care is available, it is obvious that there is a high unmet medical need for a new therapeutic concept. One reason for a missing etiologic therapy strategy is the multifactorial origin of ARDS, which leads to a large heterogeneity of patients. This review summarizes the various kinds of ARDS onset with a special focus on the role of reactive oxygen species (ROS), which are generally linked to ARDS development and progression. Taking a closer look at the data which already have been established in mouse models, this review finally proposes the translation of these results on successful antioxidant use in a personalized approach to the ICU patient as a potential adjuvant to standard ARDS treatment.

biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy
Is intravenous cholangiography still useful?

M. Goodman,H. Ansel,J. Vennes,R. Lasser,S. Silvis

DOI: https://doi.org/10.5555/uri:pii:0016508580902383

IF: 29.4

1980-10-01

Gastroenterology

Abstract:A retrospective study was performed to determine the usefulness of the intravenous cholangiogram for evaluation of common bile duct disease. Using interpretations obtained by chart review, 128 intravenous cholangiograms were categorized according to common bile duct visualization. Fifty-five percent of the studies were considered technically adequate for interpretation, while 23% and 22% were suboptimal and nondiagnostic, respectively. The intravenous cholangiogram diagnoses were verified when possible by comparison with the findings of: (a) endoscopic retrograde cholangiography, (b) operative cholangiography, (c) choledochotomy, or (d) autopsy. In verified studies of adequate intravenous cholangiograms, the diagnostic error rate was 40%, largely owing to missed stones. We conclude that the intravenous cholangiogram is usually unreliable for biliary tract evaluation, and should be replaced by alternative studies such as endoscopic or transhepatic cholangiography.
Efficacy and safety of several common drugs in the treatment of acute respiratory distress syndrome: A systematic review and network meta-analysis

Qing-Kuo Liu,Guo-Han Xiang,Wen-Li Liu,Jin-Yan Dong,Yu-Qi Wen,Hao Hao

DOI: https://doi.org/10.1097/md.0000000000040472

IF: 1.6

2024-11-28

Medicine

Abstract:Acute respiratory distress syndrome (ARDS) is a clinical syndrome characterized by the onset of illness within 1 week, radiographic evidence of bilateral lung infiltrates, non-cardiogenic pulmonary edema, and refractory hypoxemia. [ 1 ] ARDS is a common condition in critically ill patients. According to a large clinical observational study, [ 2 ] the incidence of ARDS in critically ill patients is 10.4%, accounting for 23.4% of patients requiring mechanical ventilation. Hospital mortality rates for mild, moderate, and severe ARDS were 34.9%, 40.3%, and 46.1%, respectively. During the global Coronavirus Disease 2019 (COVID-19), studies [ 3 ] have shown that ARDS induced by viral pneumonia is one of the main causes of death among COVID-19 hospitalized patients. The incidence of ARDS in COVID-19 hospitalized patients is 33%, with an average mortality rate of 39%. The etiology of ARDS includes direct lung injury (bacterial or viral pneumonia, aspiration pneumonia, and lung contusion) and extrapulmonary factors (sepsis, severe trauma, major surgery, and massive transfusions). The pathogenesis of ARDS is not yet fully understood. However, it is generally believed that its main mechanism involves a cascade of amplified inflammatory responses. As for the treatment of ARDS, effective measures primarily include lung-protective ventilation, control of driving pressure, prone positioning, and extracorporeal membrane oxygenation. [ 4 ]

medicine, general & internal
Innovations in protective mechanical ventilation for acute respiratory distress syndrome management

Denise Battaglini Sergio Lassola Marcus J. Schultz Patricia RM Rocco a Anesthesia and Intensive Care,IRCCS Ospedale Policlinico San Martino,Genova,Italyb Department of Surgical Sciences and Integrated Diagnostics (DISC),University of Genova,Genova,Italyc Anesthesia and Intensive Care 1,Santa Chiara Hospital,APSS,Trento,Italyd Department of Intensive Care,Amsterdam UMC,Location AMC,Amsterdam,The Netherlandse Department of Anesthesia,General Intensive Care and Pain Management,Medical University Wien,Vienna,Austriaf Nuffield Department of Medicine,University of Oxford,Oxford,UKg Laboratory of Pulmonary Investigation,Carlos Chagas Filho Institute of Biophysics,Federal University of Rio de Janeiro,Rio de Janeiro,Brazil

DOI: https://doi.org/10.1080/17434440.2024.2393773

IF: 3.439

2024-08-21

Expert Review of Medical Devices

Abstract:KEYWORDS: Managing acute respiratory distress syndrome (ARDS) poses significant challenges due to its heterogeneous nature. As of 2024, the updated global definition of ARDS now includes patients receiving noninvasive ventilation or high-flow oxygen therapy, facilitating earlier diagnosis [ Citation 1 ]. Despite advancements in identifying ARDS sub-phenotypes, integration of these novel entities into clinical practice remains uncertain. Moreover, effective therapies for ARDS are limited, with persistently high mortality rates [ Citation 2 ].

engineering, biomedical
Recent advances in the understanding and management of ARDS

Tyler J Peck,Kathryn A Hibbert

DOI: https://doi.org/10.12688/f1000research.20411.1

2019-11-22

F1000Research

Abstract:The acute respiratory distress syndrome (ARDS) remains a common and highly morbid condition despite advances in the understanding and management of this complex critical illness. Recent work has illuminated the heterogeneity within ARDS and demonstrated the likely impact of heterogeneity on the identification of effective therapeutic interventions. Despite these challenges, new data have also informed the standard of care for ARDS and have resulted in the re-evaluation of previously established therapies, including ventilation strategies, pharmacologic interventions, and rescue therapies. As the field of ARDS continues to evolve, innovative approaches will be needed to further define phenotypes within ARDS and design targeted clinical trials.

English Else
Renin-angiotensin-system, a potential pharmacological candidate, in acute respiratory distress syndrome during mechanical ventilation

Di Wang,Xiao-qing Chai,Costan G. Magnussen,Graeme R. Zosky,Shu-hua Shu,Xin Wei,Shan-shan Hu

DOI: https://doi.org/10.1016/j.pupt.2019.101833

IF: 3.282

2019-01-01

Pulmonary Pharmacology & Therapeutics

Abstract:While effective treatments for acute respiratory distress syndrome (ARDS) are lacking, mechanical lung ventilation can sustain adequate gas exchange in critically ill patients with respiratory failure due to ARDS. However, as a result of the phenomenon of ventilator-induced lung injury (VILI), there is an increasing need to seek beneficial pharmacological therapies for ARDS. Recent studies have suggested the renin-angiotensin system (RAS), which consists of the ACE/Ang-II/AT1R axis and ACE2/Ang-(1–7)/MasR axis, plays a dual role in the pathogenesis of ARDS and VILI. This review highlights the deleterious action of ACE/Ang-II/AT1R axis and the beneficial role of ACE2/Ang-(1–7)/MasR axis, as well as AT2R, in VILI and ARDS, and also discusses the possibility of targeting RAS components with pharmacological interventions to improve outcomes in ARDS.
A case of neurofibromatosis associated with clitoral enlargement and hypertension.

K. Nonomura,T. Kanno,M. Tanaka,K. Kanagawa,M. Kubota,Y. Asano,M. Togashi,T. Koyanagi

DOI: https://doi.org/10.1016/0022-3468(92)90122-N

IF: 2.549

Journal of Pediatric Surgery

Abstract:
World summit against cancer for the new millennium: 4th February 2000 charter of Paris against cancer.

T. Taguchi

2000-11-01

Abstract:
Nanomedicine for acute respiratory distress syndrome: The latest application, targeting strategy, and rational design

Qi Qiao,Xiong Liu,Ting Yang,Kexin Cui,Li Kong,Conglian Yang,Zhiping Zhang

DOI: https://doi.org/10.1016/j.apsb.2021.04.023

Abstract:Acute respiratory distress syndrome (ARDS) is characterized by the severe inflammation and destruction of the lung air-blood barrier, leading to irreversible and substantial respiratory function damage. Patients with coronavirus disease 2019 (COVID-19) have been encountered with a high risk of ARDS, underscoring the urgency for exploiting effective therapy. However, proper medications for ARDS are still lacking due to poor pharmacokinetics, non-specific side effects, inability to surmount pulmonary barrier, and inadequate management of heterogeneity. The increased lung permeability in the pathological environment of ARDS may contribute to nanoparticle-mediated passive targeting delivery. Nanomedicine has demonstrated unique advantages in solving the dilemma of ARDS drug therapy, which can address the shortcomings and limitations of traditional anti-inflammatory or antioxidant drug treatment. Through passive, active, or physicochemical targeting, nanocarriers can interact with lung epithelium/endothelium and inflammatory cells to reverse abnormal changes and restore homeostasis of the pulmonary environment, thereby showing good therapeutic activity and reduced toxicity. This article reviews the latest applications of nanomedicine in pre-clinical ARDS therapy, highlights the strategies for targeted treatment of lung inflammation, presents the innovative drug delivery systems, and provides inspiration for strengthening the therapeutic effect of nanomedicine-based treatment.
The Acute Respiratory Distress Syndrome in 2013

Michael A Matthay,Yuanlin Song,Chunxue Bai,Kirk D Jones

DOI: https://doi.org/10.1186/2213-0802-1-10

2013-01-01

Translational Respiratory Medicine

Abstract:Acute lung injury and the acute respiratory distress syndrome are major causes of morbidity and mortality in critically ill patients. This review focuses on new developments in definitions, epidemiology, clinical and basic research, and promising new directions in treatment. There is new information about the potential contribution of environmental factors, especially exposure to cigarette smoke. Pathologic findings in ARDS have been limited to case reports of open lung biopsies and post-mortem studies but there is some new information from a recent pathology study relative to the frequency of diffuse alveolar damage and the severity of arterial hypoxemia. Further, therapy with lung-protective ventilation and fluid conservative protocol has improved outcomes, but several new trials are in progress to test several promising strategies.
Novel Biomarkers for Acute Respiratory Distress Syndrome: Genetics, Epigenetics and Transcriptomics

Fei Zheng,Yihang Pan,Yang,Congli Zeng,Xiangming Fang,Qiang Shu,Qixing Chen

DOI: https://doi.org/10.2217/bmm-2021-0749

2022-01-01

Biomarkers in Medicine

Abstract:Acute respiratory distress syndrome (ARDS) can be induced by multiple clinical factors, including sepsis, acute pancreatitis, trauma, intestinal ischemia/reperfusion and burns. However, these factors alone may poorly explain the risk and outcomes of ARDS. Emerging evidence suggests that genomic-based or transcriptomic-based biomarkers may hold the promise to establish predictive or prognostic stratification methods for ARDS, and also to help in the development of novel therapeutic targets for ARDS. Notably, genetic/epigenetic variations correlated with susceptibility and prognosis of ARDS and circulating microRNAs have emerged as potential biomarkers for diagnosis or prognosis of ARDS. Although limited by sample size, ethnicity and phenotypic heterogeneity, ongoing genetic/transcriptomic research contributes to the characterization of novel biomarkers and ultimately helps to develop innovative therapeutics for ARDS patients.

Conformational properties of the disaccharide building units of hyaluronan.

Acute Respiratory Distress Syndrome: Bench-to-Bedside Approaches to Improve Drug Development.

Acute Respiratory Distress Syndrome: Bench‐to‐Bedside Approaches to Improve Drug Development

Challenges in ARDS Definition, Management, and Identification of Effective Personalized Therapies

Pulmonary drug delivery for acute respiratory distress syndrome

Management of the acute respiratory distress syndrome

Share First, Save Later: Performance of Self through Snapchat Stories

Investigational pharmacological agents for the treatment of ARDS

[Consensus conference: home intravenous antibiotic treatment for cystic fibrosis. The Sira Carrasco Foundation. 26 April 2002].

Signaling pathways and potential therapeutic targets in acute respiratory distress syndrome (ARDS)

Antioxidants as Therapeutic Agents in Acute Respiratory Distress Syndrome (ARDS) Treatment—From Mice to Men

Is intravenous cholangiography still useful?

Efficacy and safety of several common drugs in the treatment of acute respiratory distress syndrome: A systematic review and network meta-analysis

Innovations in protective mechanical ventilation for acute respiratory distress syndrome management

Recent advances in the understanding and management of ARDS

Renin-angiotensin-system, a potential pharmacological candidate, in acute respiratory distress syndrome during mechanical ventilation

A case of neurofibromatosis associated with clitoral enlargement and hypertension.

World summit against cancer for the new millennium: 4th February 2000 charter of Paris against cancer.

Nanomedicine for acute respiratory distress syndrome: The latest application, targeting strategy, and rational design

The Acute Respiratory Distress Syndrome in 2013

Novel Biomarkers for Acute Respiratory Distress Syndrome: Genetics, Epigenetics and Transcriptomics